Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716565 | 0.89 | KDM4E (0.48) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12479145 | 0.89 | CHRNA7 (0.48) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12479112 | 0.78 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12480290 | 0.78 | CHRNA7 (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12480797 | 0.78 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12479621 | 0.78 | CHRNA7 (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6479683 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL26757972 | 0.72 | MAOA (0.40) | CHRNA7DRD2DRD1DRD4DRD5 | |
| SCHEMBL168661 | 0.71 | CHRNA7 (0.60) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6823728 | 0.70 | ADRA2A (0.38) | ADRA2ANPSR1HTTPTK2BAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8815843-B2 | Compounds and methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8791132-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2675458-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | Medivation Technologies, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2675459-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | Medivation Technologies, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012112966-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | ADRA2A 11/4885ADRA2B 2/4885ADRA2C 6/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | ADRA2A 4/4885ADRA2B 2/4885ADRA2C 3/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | ADRA2A 11/4885ADRA2B 2/4885ADRA2C 6/4885 |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | ADRA2A 11/4885ADRA2B 2/4885ADRA2C 6/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | ADRA2A 4/4885ADRA2B 2/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.